Clinical Trial Update: A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for ONTAK (denileukin diftitox) in relapsed or refractory B-cell non-Hodgkin lymphoma; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• ONTAK (denileukin diftitox)

Snippet

Sponsor: Eisai Inc. | Conditions: Lymphoma, B-Cell | Phase 2 | Status: COMPLETED